Lightstone Ventures

We don’t just invest in ideas. We invest in people.

Lightstone Ventures was founded in 2012 to empower big-thinking founders with vision and commitment to bring innovative therapeutics to patients in need

Our experience spans all stages of company growth

Our team collectively has nearly 100 years of company-building experience We have been part of start-up ventures of all stages and played a critical role in evaluating, guiding, and building successful healthcare companies

We are partners in company building

Fostering successful companies does not just mean writing a check We not only back our companies financially, but we partner with them to navigate their day-to-day functions Our team works hands-on with founders to help establish a strategy that can transform their vision into commercially viable products

More than investors – we are guides

We invest with a long-term vision and patient capital that will fund the company through its life cycle from start-up to commercialization Using a thesis-driven investment strategy, we focus on understanding key market sectors and seeking out disruptive technologies while building and nurturing relationships with key thought leaders

Our reach is global

Our global footprint with offices in the U S , Ireland and Singapore allows us to build a network with non-U S strategic and financial funding sources, as well as exploring novel development and commercialization strategies in these geographies

Our portfolio companies succeed

Lightstone team members have been involved in some of the largest venture-backed life science exits over the last decade including: Ardian, Acceleron, ALX Oncology, Calithera BioSciences, Claret Medical, Disarm Therapeutics, MicroVention, Nimbus, Plexxikon, Portola Pharmaceuticals, Promedior, Proteolix, Ra Pharma, Tizona Therapeutics, Twelve and Zeltiq

Big Ideas, Bright Futures.

We back driven entrepreneurs developing breakthrough therapies and technologies that have the potential to be industry-first or industry-leading products

The success of a company is determined by its people, so we work closely with biotech and medtech founders to build teams with the experience and ambition necessary to achieve their goals

Our team looks for companies developing first-in-class drugs, across all modalities including small molecules, biologics and cell and gene therapies We are focused on several disease areas including the central nervous system (CNS), immunology with particular interest in autoimmune diseases, next-generation approaches in oncology and ophthalmology

We look for founders with big ideas targeting the convergence of technology, medicine and consumer health We see promise in companies focused on personalized medicines and targeted therapeutics that leverage data analytics and scientific platforms—groundbreaking medical technologies that address major diseases across immunology, cardiovascular, neurology and ophthalmology

Acceleron Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat serious and rare diseases The company successfully completed an IPO in 2013

Alchemab Therapeutics is using deep learning and cutting edge science to develop novel drugs for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies and the adaptive immune system

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians

• Location:Menlo Park, CA and Singapore ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system The company successfully completed an IPO in 2020 (NASDAQ: ALXO)

Apreo Health is a development stage medical technology company that is developing innovative, globally applicable treatments for pulmonary disease

• Lead:Hanson S

• Gifford, III Ardian is a medical device company developing catheter-based therapies to treat hypertension and related conditions Ardian was incubated within The Foundry, the premier medical technology incubator, and was acquired by Medtronic (NYSE: MDT) in 2011

• Lead:Hank Plain, Mike Carusi Atsena Therapeutics is a clinical-stage gene therapy company focused on developing novel therapeutics to prevent or reverse blindness

Avidia is a biopharmaceutical company discovering and developing a new class of human therapeutic proteins called Avimer™ The company was acquired by Amgen (NASDAQ: AMGN) in 2006

Cabochon Aesthetics is a medical device company developing effective, scientific solutions for the aesthetic treatment of cellulite The company was incubated within The Foundry, the premier medical technology incubator, and was acquired by Ulthera in 2014